Jeffrey B Driban1, Grace H Lo2, Charles B Eaton3, Kate L Lapane4, Michael Nevitt5, William F Harvey6, Charles E McCulloch5, Timothy E McAlindon6. 1. Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box #406, Boston, MA 02111, USA. 2. Houston Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, USA. 3. Departments of Family Medicine and Epidemiology, Alpert Medical School of Brown University, and Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket, RI, USA. 4. Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA. 5. Department of Epidemiology and Biostatistics at the University of California, San Francisco, CA, USA. 6. Division of Rheumatology, Tufts Medical Center, Boston, MA, USA.
Abstract
BACKGROUND: We conducted an exploratory analysis of osteoarthritis progression among medication users in the Osteoarthritis Initiative to identify interventions or pathways that may be associated with disease modification and therefore of interest for future clinical trials. METHODS: We used participants from the Osteoarthritis Initiative with annual medication inventory data between the baseline and 36-month follow-up visit (n = 2938). Consistent medication users were defined for each medication classification as a participant reporting at all four annual visits that they were regularly using an oral prescription medication at the time of the visit. The exploratory analysis focused on medication classes with 40 or more users. The primary outcome measures were medial tibiofemoral joint space width change and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) knee pain score change (12-36-month visits). Within each knee, we explored eight comparisons between users and matched or unmatched nonusers (defined two ways). An effect size of each comparison was calculated. Medication classes had potential signals if (a) both knees had less progression among users compared with nonusers, or (b) there was less progression based on structure and symptoms in one knee. RESULTS: We screened 28 medication classes. Six medication classes had signals for fewer structural changes and better knee pain changes: alpha-adrenergic blockers, antilipemic (excluding statins and fibric acid), anticoagulants, selective serotonin reuptake inhibitors, antihistamines, and antineoplastic agents. Four medication classes had signals for structural changes alone: anti-estrogen (median effect size = 0.28; range = -0.41-0.64), angiotensin-converting enzyme inhibitors (median effect size = 0.13; range = -0.08-0.28), beta-adrenergic blockers (median effect size = 0.09; range = 0.01-0.30), and thyroid agents (median effect size = 0.04; range = -0.05-0.14). Thiazide diuretics had evidence for symptom modification (median effect size = -0.12; range = -0.24-0.04). CONCLUSIONS: Users of neurovascular, antilipemic, or hormonal interventions may have less disease progression compared with nonusers.
BACKGROUND: We conducted an exploratory analysis of osteoarthritis progression among medication users in the Osteoarthritis Initiative to identify interventions or pathways that may be associated with disease modification and therefore of interest for future clinical trials. METHODS: We used participants from the Osteoarthritis Initiative with annual medication inventory data between the baseline and 36-month follow-up visit (n = 2938). Consistent medication users were defined for each medication classification as a participant reporting at all four annual visits that they were regularly using an oral prescription medication at the time of the visit. The exploratory analysis focused on medication classes with 40 or more users. The primary outcome measures were medial tibiofemoral joint space width change and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) knee pain score change (12-36-month visits). Within each knee, we explored eight comparisons between users and matched or unmatched nonusers (defined two ways). An effect size of each comparison was calculated. Medication classes had potential signals if (a) both knees had less progression among users compared with nonusers, or (b) there was less progression based on structure and symptoms in one knee. RESULTS: We screened 28 medication classes. Six medication classes had signals for fewer structural changes and better knee pain changes: alpha-adrenergic blockers, antilipemic (excluding statins and fibric acid), anticoagulants, selective serotonin reuptake inhibitors, antihistamines, and antineoplastic agents. Four medication classes had signals for structural changes alone: anti-estrogen (median effect size = 0.28; range = -0.41-0.64), angiotensin-converting enzyme inhibitors (median effect size = 0.13; range = -0.08-0.28), beta-adrenergic blockers (median effect size = 0.09; range = 0.01-0.30), and thyroid agents (median effect size = 0.04; range = -0.05-0.14). Thiazide diuretics had evidence for symptom modification (median effect size = -0.12; range = -0.24-0.04). CONCLUSIONS: Users of neurovascular, antilipemic, or hormonal interventions may have less disease progression compared with nonusers.
Authors: Timothy M Griffin; Beverley Fermor; Janet L Huebner; Virginia B Kraus; Ramona M Rodriguiz; William C Wetsel; Li Cao; Lori A Setton; Farshid Guilak Journal: Arthritis Res Ther Date: 2010-07-06 Impact factor: 5.156
Authors: Ehsan Saadat; Bjoern Jobke; Bill Chu; Ying Lu; Jonathan Cheng; Xiaojuan Li; Michael D Ries; Sharmila Majumdar; Thomas M Link Journal: Eur Radiol Date: 2008-05-20 Impact factor: 5.315
Authors: Theun Antonius Hoeven; Maryam Kavousi; Stefan Clockaerts; Hanneke J M Kerkhof; Joyce B van Meurs; Oscar Franco; Albert Hofman; Patrick Bindels; Jacqueline Witteman; Sita Bierma-Zeinstra Journal: Ann Rheum Dis Date: 2012-05-06 Impact factor: 19.103
Authors: Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman Journal: Ann Intern Med Date: 2007-12-17 Impact factor: 25.391
Authors: Manal A Abdel-Aziz; Helmy M S Ahmed; Aziza A El-Nekeety; Mosaad A Abdel-Wahhab Journal: Inflammopharmacology Date: 2021-11-09 Impact factor: 4.473
Authors: Alexandra A Leaney; Jenna R Lyttle; Julian Segan; Donna M Urquhart; Flavia M Cicuttini; Louisa Chou; Anita E Wluka Journal: Cochrane Database Syst Rev Date: 2022-10-21
Authors: Aqeel M Alenazi; Sakher M Obaidat; Mohammed M Alshehri; Shaima Alothman; Corey Gray; Jason Rucker; Lemuel R Waitman; Patricia M Kluding Journal: Pain Med Date: 2020-05-01 Impact factor: 3.750
Authors: Julie E Davis; Matthew S Harkey; Shao-Hsien Liu; Kate Lapane; Lori Lyn Price; Bing Lu; Grace H Lo; Charles B Eaton; Mary F Barbe; Timothy E McAlindon; Jeffrey B Driban Journal: ACR Open Rheumatol Date: 2019-07-25
Authors: Aqeel M Alenazi; Bader A Alqahtani; Vishal Vennu; Mohammed M Alshehri; Ahmad D Alanazi; Saud M Alrawaili; Kamlesh Khunti; Neil A Segal; Saad M Bindawas Journal: Int J Environ Res Public Health Date: 2021-04-21 Impact factor: 3.390